Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
Rhea-AI Summary
Cryoport (NASDAQ: CYRX) reported FY2025 revenue of $176.2 million, up 12% year-over-year and above prior guidance, with Life Sciences Services revenue of $96.5 million (+18%) and Life Sciences Products revenue of $79.7 million (+7%).
The company supported a record 760 clinical trials and 20 commercial therapies, ended FY2025 with $411.2 million in cash and provided 2026 revenue guidance of $190.0M–$194.0M (8%–10% growth).
Positive
- Revenue exceeded guidance: $176.2M FY2025
- Life Sciences Services growth: +18% FY2025
- Commercial CGT revenue: $33.4M (+29% YoY)
- Adjusted EBITDA improvement: $12M YoY improvement
- Strong liquidity: $411.2M cash and short-term investments
Negative
- Continuing operations loss: $34.0M FY2025
- Non-GAAP adjusted net loss: $34.0M FY2025
- Repurchased shares reduced cash by $10.0M
Key Figures
Market Reality Check
Peers on Argus
While CYRX fell 2.49%, key logistics peers like RLGT, FWRD, PBI, FLX, and PAL each showed gains between 1.6% and 5.83%, indicating a stock-specific move rather than a sector-driven shift.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 04 | Q3 2025 earnings | Positive | -7.5% | Q3 2025 revenue growth and guidance raise with margin improvement. |
| Nov 04 | Q3 2025 earnings | Positive | -7.5% | Same Q3 2025 results emphasizing higher CGT revenue and cash. |
| Aug 05 | Q2 2025 earnings | Positive | +29.8% | Strong Q2 revenue growth and DHL partnership with capital infusion. |
| May 07 | Q1 2025 earnings | Positive | +23.3% | Q1 revenue growth and expanded clinical trial support with DHL deal. |
| Mar 04 | FY 2024 earnings | Positive | +30.6% | FY 2024 revenue in line with guidance and growing CGT therapies. |
Earnings releases have often triggered sizable moves, with both sharp rallies and notable selloffs following similar updates.
Over the past year, Cryoport’s earnings updates have highlighted consistent revenue growth, expanding commercial cell & gene therapy exposure, and improving margins. Q1–Q3 2025 results featured double‑digit top‑line growth, a DHL partnership, and a rising clinical trial count. The FY 2024 report set the baseline with $228.4M revenue and 701 trials. Today’s FY 2025 release showing $176.2M revenue from continuing operations and 760 trials fits into this trajectory of operational scaling and portfolio refocus.
Historical Comparison
In the past year, CYRX published 5 earnings updates with an average move of 13.76% in either direction. Today’s modest -2.49% reaction sits well inside that historical volatility band.
Earnings from FY 2024 through Q1–Q3 2025 showed steady revenue growth, rising commercial CGT exposure, and margin gains, culminating in FY 2025 results with higher gross margin and larger trial and therapy counts.
Market Pulse Summary
This announcement details FY 2025 results with revenue of $176.2M, improved gross margin of 47.1%, and expanded support to 760 global clinical trials and 20 commercial therapies. The company also closed a strategic divestiture, ended the year with $411.2M in cash and investments, and guided 2026 revenue to $190M–$194M. Investors may watch how trial conversions, new BLA/MAA approvals, and cost discipline track against that guidance and past earnings reactions.
Key Terms
biologics license applications (bla) regulatory
marketing authorization applications (maa) regulatory
cGMP medical
form 10-k regulatory
AI-generated analysis. Not financial advice.
- FY 2025 revenue increased to
$176.2 million - Life Sciences Services revenue grew
18% year-over-year in FY 2025, including a22% rise in BioStorage/BioServices revenue - Commercial cell and gene therapy revenue increased
29% year-over-year to$33.4 million - Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025
- Full-year 2026 revenue guidance of
$190 million $194 million 8% -10% growth y-o-y)
Jerrell Shelton, CEO of Cryoport, commented, "2025 was a year of strong progress for Cryoport. We delivered full-year revenue of
"We continued to execute on our strategy of expanding our revenue streams and capturing more revenue per client as our Life Sciences Services revenue increased
"Despite macro challenges, our Life Sciences Products segment grew
"We also increased our investments into Cryoport Systems to support the traction that we are seeing across our broad portfolio of CGT clients. These targeted investments include the launch of our Global Supply Chain Center in
"Importantly, in 2025 we formed a strategic partnership with DHL Group, which included DHL's acquisition of CRYOPDP, providing a substantial capital infusion. Over time, we believe this relationship will enhance our positioning in the EMEA and APAC regions and strengthen our competitive industry profile. As part of our continuing strategic initiative to embed our market-leading solutions into the CGT ecosystem and improve our growth trajectory, we expanded our global partnerships by entering into strategic collaborations with Cardinal Health and Parexel.
"As we enter 2026 and balance the global macro puts and takes, we believe that our full-year revenue guidance of
In tabular form, Q4 2025 and FY 2025 revenue compared to Q4 2024 and FY 2024, respectively, were as follows:
Cryoport, Inc. and Subsidiaries | ||||||
Revenue | ||||||
Three Months Ended | Years Ended | |||||
(in thousands) | 2025 | 2024 | % Change | 2025 | 2024 | % Change |
Life Sciences Services | $ 25,005 | $ 21,476 | 16 % | $ 96,497 | $ 82,044 | 18 % |
BioLogistics Solutions | 20,305 | 17,479 | 16 % | 78,137 | 67,019 | 17 % |
BioStorage/BioServices | 4,700 | 3,997 | 18 % | 18,360 | 15,025 | 22 % |
Life Sciences Products | $ 20,445 | $ 19,976 | 2 % | $ 79,680 | $ 74,725 | 7 % |
Total Revenue | $ 45,450 | $ 41,452 | 10 % | $ 176,177 | $ 156,769 | 12 % |
BioLogistics Solutions revenue increased
Revenue from the support of commercial CGTs increased
As of year-end, Cryoport supported a total of 760 global clinical trials, a net increase of 59 clinical trials over FY 2024, with 86 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:
Cryoport Supported Clinical Trials by Phase | |||
Clinical Trials | December 31, | ||
2023 | 2024 | 2025 | |
Phase 1 | 282 | 299 | 313 |
Phase 2 | 311 | 321 | 361 |
Phase 3 | 82 | 81 | 86 |
Total | 675 | 701 | 760 |
Cryoport Supported Clinical Trials by Region | |||
Clinical Trials | December 31, | ||
2023 | 2024 | 2025 | |
519 | 537 | 571 | |
EMEA | 112 | 116 | 138 |
APAC | 44 | 48 | 51 |
Total | 675 | 701 | 760 |
In Q4 2025, five Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occurred. Post quarter-end, two additional BLA filings have occurred. During the fourth quarter, Cryoport's customer, Fondazione Telethon received FDA approval for their gene therapy Waskyra for the treatment of Wiskott-Aldrich Syndrome (WAS). During the fourth quarter, Bristol Myers Squibb received supplemental approval from the European Commission (EC) to expand the label of Breyanzi® as a third line treatment for relapsed or refractory follicular lymphoma. Lastly, in late December, Cryoport's customer Inovio Pharmaceuticals' BLA filing for INO-3107 was accepted by the FDA as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP). For 2026, we anticipate 13 BLA/MAA application filings (including the two already filed), nine new therapy approvals and an additional two approvals for label/geographic expansions. In the near term, Cryoport has three clients that are anticipating new therapy approval decisions in March and April 2026.
Operational milestones
Life Sciences Services
- Launched state-of-the-art Global Supply Chain Center at the Charles de Gaulle airport in
Paris, France , with our fourth Global Supply Chain Center inSanta Ana, California targeted for opening in late 2026. - IntegriCell®, with cryopreservation service centers located near Liège,
Belgium and inHouston, Texas , onboarded its first clients from whom we will have revenues throughout 2026. - Launched cGMP sterile fulfillment/kitting services out of our Liège,
Belgium facility supporting manufacturing needs for a key commercial client and the broader market. - Cryoport Systems successfully achieved certification under ISO 21973:2020, the international standard for transportation of cells for therapeutic use published by the International Organization for Standardization (ISO), underscoring its commitment to safety and traceability within supply chain management of the rapidly expanding CGT industry.
Life Sciences Products
- MVE Biological Solutions (MVE) introduced its integrated Condition Monitoring Solutions for its SC 4/2V and 4/3V dry vapor shippers, combining MVE's trusted cryogenic systems with advanced, real-time condition monitoring technology supplied by Tec4med, a Cryoport company.
- MVE launched its new Fusion® 800 Series, the next evolution of MVE's patented, award-winning Fusion technology, a self-sustaining cryogenic freezer that eliminates the need for a continuous liquid nitrogen (LN₂) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments.
Financial Highlights
On June 11, 2025, the Company completed its previously announced divestiture of its specialty courier CRYOPDP business to DHL Supply Chain International Holding B.V. ("DHL") as a part of a strategic partnership with DHL. The divestiture and strategic partnership are expected to enhance the Company's ability to develop its business, particularly in the EMEA and APAC regions, and to provide differentiated and high-value services aligned with Cryoport's long-term growth strategy. The results of CRYOPDP, a former business within Cryoport's Life Sciences Services segment, are presented as discontinued operations for all periods presented within the Condensed Consolidated Statements of Operations and Condensed Consolidated Balance Sheets included in this press release and are also not included in the non-GAAP financial measures presented herein.
Revenue
- Total revenue for Q4 2025 was
$45.5 million $41.5 million 10% , or$4.0 million - Life Sciences Services revenue for Q4 2025 (representing
55% of our total revenue) was$25.0 million $21.5 million 16% year-over-year, including BioStorage/BioServices revenue of$4.7 million 18% year-over-year. - Life Sciences Products revenue for Q4 2025 (representing
45% of our total revenue) was$20.4 million $20.0 million 2% year-over-year.
- Life Sciences Services revenue for Q4 2025 (representing
- Total revenue for FY 2025 was
$176.2 million $156.8 million 12% , or$19.4 million - Life Sciences Services revenue for FY 2025 was
$96.5 million $82.0 million 18% year-over-year, including BioStorage/BioServices revenue of$18.4 million $15.0 million 22% year-over-year. - Life Sciences Products revenue for FY 2025 was
$79.7 million $74.7 million 7% year-over-year.
- Life Sciences Services revenue for FY 2025 was
Gross Margin
- Total gross margin was
47.8% for Q4 2025, compared to47.0% for Q4 2024.- Gross margin for Life Sciences Services was
48.6% for Q4 2025, compared to48.8% for Q4 2024. - Gross margin for Life Sciences Products was
46.8% for Q4 2025, compared to45.1% for Q4 2024.
- Gross margin for Life Sciences Services was
- Total gross margin was
47.1% for FY 2025 compared to44.4% for FY 2024.- Gross margin for Life Sciences Services was
48.8% for FY 2025, compared to46.9% for FY 2024. - Gross margin for Life Sciences Products was
45.2% for FY 2025, compared to41.7% for FY 2024.
- Gross margin for Life Sciences Services was
Operating Costs and Expenses
- Operating costs and expenses were
$31.7 million $32.2 million $119.9 million $191.3 million $63.8 million $119.9 million $127.5 million
Loss from Continuing Operations
- Loss from continuing operations was
$8.5 million $17.2 million $34.0 million $104.7 million
Net Income (Loss) – including Discontinued Operations
- Net loss for Q4 2025 was
$11.6 million $78.3 million $18.7 million $114.8 million $112.3 million - Net loss attributable to common stockholders for Q4 2025 was
$13.6 million $0.27 $70.3 million $1.40 $20.7 million $0.42 $122.8 million $2.49 - Non-GAAP adjusted net loss was
$34.0 million $69.5 million
Adjusted EBITDA from Continuing Operations
- Adjusted EBITDA from continuing operations was a negative
$1.4 million $2.9 million $5.8 $17.8 million
Cash, Cash equivalents, and Short-Term Investments
- Cryoport held
$411.2 million
Share Repurchase Programs
- During 2025, the Company purchased 1,340,608 shares of its common stock under its repurchase programs, at an average price of
$7.45 $10.0 million $63.9 million
Guidance for Full-Year Fiscal 2026
- The Company provides full-year 2026 revenue guidance in the range of
$190.0 million $194.0 million U.S. federal government shutdown, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.
Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release. |
Additional Information
Further information on Cryoport's financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport's financial performance are provided in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, which is expected to be filed with the SEC on March 6, 2026. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport's website at www.cryoportinc.com.
Earnings Conference Call Information
IMPORTANT INFORMATION: In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's business update, will be issued at 4:05 p.m. ET on Tuesday, March 3, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.
Cryoport management will host a conference call at 5:00 p.m. ET on March 3, 2026. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company's reported results. A slide deck will accompany the call.
Conference Call Information
Date: | Tuesday, March 3, 2026 |
Time: | 5:00 p.m. ET |
Dial-in numbers: | 1-800-717-1738 ( |
Confirmation code: | Request the "Cryoport Call" or Conference ID: 1189463 |
Live webcast: | 'Investor Relations' section at www.cryoportinc.com or click here.
Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software. |
The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until March 10, 2026. To access the replay, dial 1-844-512-2921 (
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX is a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."
Headquartered in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at https://x.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company's expectations about future benefits relating to the CRYOPDP divestiture and strategic partnership with DHL (collectively, the "DHL Transaction"), the Company's plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company's plans and expectations relating to its strategic pivot to expand its global partnerships, and the Company's expectation of revenue contribution from IntegriCell's cryopreservation service centers throughout 2026. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, tariffs and other trade restrictions, foreign currency fluctuations, trends in the products markets, any
Cryoport, Inc. and Subsidiaries | ||||
Condensed Consolidated Statements of Operations | ||||
Three Months Ended | Years Ended | |||
(in thousands, except share and per share data) | 2025 | 2024 | 2025 | 2024 |
Revenue | ||||
Life Sciences Services revenue | $ 25,005 | $ 21,476 | $ 96,497 | $ 82,044 |
Life Sciences Products revenue | 20,445 | 19,976 | 79,680 | 74,725 |
Total revenue | 45,450 | 41,452 | 176,177 | 156,769 |
Cost of revenue: | ||||
Cost of services revenue | 12,859 | 10,987 | 49,429 | 43,564 |
Cost of products revenue | 10,880 | 10,972 | 43,694 | 43,548 |
Total cost of revenue | 23,739 | 21,959 | 93,123 | 87,112 |
Gross margin | 21,711 | 19,493 | 83,054 | 69,657 |
Operating costs and expenses: | ||||
Selling, general and administrative | 27,276 | 28,091 | 102,819 | 109,809 |
Engineering and development | 4,466 | 4,155 | 17,041 | 17,710 |
Impairment loss | - | - | - | 63,809 |
Total operating costs and expenses: | 31,742 | 32,246 | 119,860 | 191,328 |
Loss from operations | (10,031) | (12,753) | (36,806) | (121,671) |
Other income (expense): | ||||
Investment income | 3,357 | 1,427 | 9,798 | 9,895 |
Interest expense | (634) | (578) | (2,361) | (3,977) |
Gain on extinguishment of debt, net | - | - | - | 18,505 |
Other income (expense), net | (87) | (5,402) | (2,801) | (7,101) |
Income (loss) before provision for income taxes | (7,395) | (17,306) | (32,170) | (104,349) |
Provision for income taxes | (1,126) | 134 | (1,799) | (359) |
Income (loss) from continuing operations | $ (8,521) | $ (17,172) | $ (33,969) | $ (104,708) |
Income (loss) from discontinued operations, net | (3,123) | (1,497) | 112,270 | (10,048) |
Net income (loss) | $ (11,644) | $ (18,669) | $ 78,301 | $ (114,756) |
Paid-in-kind dividend on Series C convertible preferred stock | (2,000) | (2,000) | (8,000) | (8,000) |
Net income (loss) attributable to common stockholders | $ (13,644) | $ (20,669) | $ 70,301 | $ (122,756) |
Net income (loss) per share attributable to common stockholders: | ||||
Basic | $ (0.27) | $ (0.42) | $ 1.40 | $ (2.49) |
Weighted average common shares issued and outstanding: | ||||
Basic | 49,759,264 | 49,616,806 | 50,071,665 | 49,349,624 |
Cryoport, Inc. and Subsidiaries | ||
Condensed Consolidated Balance Sheets | ||
December 31, | ||
2025 | 2024 | |
(in thousands) | ||
Current assets | ||
Cash and cash equivalents | $ 250,494 | $ 34,137 |
Short-term investments | 160,714 | 216,460 |
Accounts receivable, net | 33,359 | 25,304 |
Inventories | 23,188 | 21,476 |
Prepaid expenses and other current assets | 8,419 | 7,943 |
Current assets held for sale | - | 36,251 |
Total current assets | 476,174 | 341,571 |
Property and equipment, net | 85,448 | 80,013 |
Operating lease right-of-use assets | 39,720 | 39,920 |
Intangible assets, net | 138,082 | 147,927 |
Goodwill | 22,400 | 20,569 |
Deposits | 2,092 | 1,951 |
Deferred tax assets | 1,073 | 842 |
Long-term assets held for sale | - | 70,699 |
Total assets | $ 764,989 | $ 703,492 |
Current liabilities | ||
Accounts payable and other accrued expenses | $ 15,283 | $ 15,895 |
Accrued compensation and related expenses | 12,980 | 11,209 |
Deferred revenue | 943 | 1,061 |
Current portion of operating lease liabilities | 4,133 | 3,399 |
Current portion of finance lease liabilities | 422 | 315 |
Current portion of convertible senior notes, net | 185,094 | 14,298 |
Current portion of notes payable | 163 | 143 |
Current portion of contingent consideration | - | 2,808 |
Current liabilities held for sale | - | 15,435 |
Total current liabilities | 219,018 | 64,563 |
Convertible senior notes, net | - | 183,919 |
Notes payable, net | 1,087 | 1,114 |
Operating lease liabilities, net | 39,078 | 38,551 |
Finance lease liabilities, net | 741 | 800 |
Deferred tax liabilities | 1,354 | 804 |
Other long-term liabilities | 444 | 295 |
Contingent consideration, net | 629 | 3,751 |
Long-term liabilities held for sale | - | 7,797 |
Total liabilities | 262,351 | 301,594 |
Total stockholders' equity | 502,638 | 401,898 |
Total liabilities and stockholders' equity | $ 764,989 | $ 703,492 |
Note Regarding Use of Non-GAAP Financial Measures
To supplement our financial statements, which are presented on the basis of
Adjusted operating costs and expenses is defined as operating costs and expenses, excluding impairment losses, if any. Adjusted net loss is defined as net income (loss), excluding impairment losses, net gain on extinguishment of debt, and income (loss) from discontinued operations, including gain on sale, if any. Management believes these measures, when read in conjunction with, and as supplemental to, the corresponding GAAP financial measures, provide useful measures to investors of Cryoport's expenses and operating results, meaningful comparisons with historical results, and insight into Cryoport's operating performance.
Adjusted EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized loss on investments, foreign currency loss, net gain on extinguishment of debt, impairment loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.
Management believes that adjusted EBITDA from continuing operations provides a useful measure of Cryoport's operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport's ongoing operating performance. Further, management and the Company's board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding of Cryoport's comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA from continuing operations is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA from continuing operations, when read in conjunction with Cryoport's GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport's ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport's underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport's underlying business.
Cryoport, Inc. and Subsidiaries | ||||
Reconciliation of GAAP operating cost and expenses to Non-GAAP adjusted operating cost and expenses | ||||
Three Months Ended | Years Ended | |||
2025 | 2024 | 2025 | 2024 | |
(in thousands) | ||||
GAAP operating costs and expenses | $ 31,742 | $ 32,246 | $ 119,860 | $ 191,328 |
Non-GAAP adjustments to operating costs and expenses | ||||
Impairment loss | — | — | — | (63,809) |
Non-GAAP adjusted operating costs and expenses | $ 31,742 | $ 32,246 | $ 119,860 | $ 127,519 |
Cryoport, Inc. and Subsidiaries | ||||
Reconciliation of GAAP net income (loss) to Non-GAAP adjusted net income (loss) | ||||
Three Months Ended | Years Ended | |||
2025 | 2024 | 2025 | 2024 | |
(in thousands) | ||||
GAAP net income (loss) | $ (11,644) | $ (18,670) | $ 78,301 | $ (114,756) |
Non-GAAP adjustments to net income (loss) | ||||
Income (loss) from discontinued operations, including gain on sale | (3,123) | — | 112,270 | — |
Gain on extinguishment of debt, net | — | — | — | 18,505 |
Impairment loss | — | — | — | (63,809) |
Non-GAAP adjusted net loss | $ (8,521) | $ (18,670) | $ (33,969) | $ (69,452) |
Cryoport, Inc. and Subsidiaries | ||||
Reconciliation of GAAP loss from continuing operations to adjusted EBITDA | ||||
(unaudited) | ||||
Three Months Ended | Years Ended | |||
2025 | 2024 | 2025 | 2024 | |
(in thousands) | ||||
GAAP loss from continuing operations | $ (8,521) | $ (17,172) | $ (33,969) | $ (104,708) |
Non-GAAP adjustments to loss: | ||||
Depreciation and amortization expense | 6,355 | 5,992 | 25,153 | 23,565 |
Acquisition and integration costs | 6 | 3 | 75 | 655 |
Cost reduction initiatives | — | 310 | 642 | 842 |
Investment income | (3,357) | (1,427) | (9,798) | (9,895) |
Unrealized loss on investments | 82 | 2,445 | 702 | 5,038 |
Foreign currency loss | 248 | 3,130 | 2,769 | 2,352 |
Interest expense, net | 634 | 579 | 2,361 | 3,977 |
Stock-based compensation expense | 2,431 | 3,644 | 10,066 | 16,567 |
Gain on extinguishment of debt, net | — | — | — | (18,505) |
Impairment loss | — | — | — | 63,809 |
Change in fair value of contingent consideration | — | (225) | (5,178) | (1,827) |
Income taxes | 1,126 | (134) | 1,799 | 359 |
Other adjustments | (401) | — | (401) | — |
Adjusted EBITDA from continuing operations | $ (1,397) | $ (2,855) | $ (5,779) | $ (17,771) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-reports-fourth-quarter-and-full-year-2025-financial-results-302703027.html
SOURCE Cryoport, Inc.
FAQ
How much revenue did Cryoport (CYRX) report for FY2025 and was it above guidance?
What is Cryoport's FY2026 revenue guidance for CYRX and implied growth rate?
How did Cryoport's Life Sciences Services and Products perform in FY2025 (CYRX)?
What cash and liquidity did Cryoport (CYRX) report at year-end 2025?
How many clinical trials and commercial therapies did Cryoport (CYRX) support by year-end 2025?
